Skip to main content

Advertisement

Fig. 3 | Cancer Communications

Fig. 3

From: Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo

Fig. 3

Azithromycin enhances TRAIL-induced cell death in HCT-116 and SW480 cells. a HCT-116 and SW480 cells were treated with azithromycin (50 and 100 µmol/L) and TRAIL (15.625 or 100 nmol/L, respectively) for 24 h. Apoptosis was detected by annexin V-FITC/PI staining and flow cytometry analysis. The cell death rate is the sum of the percentages of early, late apoptotic and necrotic cells. *P < 0.05 and **P < 0.01 vs. control. #P < 0.05 and ##P < 0.01 vs. TRAIL alone. b Cell lines were exposed to azithromycin (50 or 100 µmol/L) and/or TRAIL (10, 15.625 or 100 nmol/L) for 10 h. The expression levels of proteins were detected by Western blot analysis. c zVAD.fmk reversed the synergistic inhibitory effect of azithromycin and TRAIL. Both cell lines were treated with azithromycin (50 µmol/L), TRAIL (100 nmol/L) and zVAD.fmk (40 µmol/L) (zVAD.fmk pretreatment for 0.5 h) for 48 h. *P < 0.05. d zVAD.fmk also significantly reduced the expression level of cleaved-PARP. Cell lines were exposed to azithromycin (50 or 100 µmol/L), TRAIL (15.625 or 50 nmol/L) and zVAD.fmk (40 µmol/L) (zVAD.fmk pretreatment for 0.5 h) for 10 h. Each experiment was repeated three times. The data represent the mean ± SD of three independent experiments. AZM represents azithromycin

Back to article page